ARTICLE | Clinical News
RG-101: Interim Phase II data
February 22, 2016 8:00 AM UTC
Interim data from 38 treatment-naive patients with chronic HCV genotype 1 or 4 infection in a Phase II trial showed that a single subcutaneous injection of 2 mg/kg RG-101 followed by an approved once-...